Article Text

Download PDFPDF
Letter
A randomised placebo-controlled trial of topical steroid in presumed viral conjunctivitis
  1. Albert Chak-ming Wong1,
  2. Shiu Ting Mak2
  1. 1Department of Ophthalmology, Union Hospital, Hong Kong
  2. 2Department of Ophthalmology, Caritas Medical Centre, Hong Kong
  1. Correspondence to Dr Albert Chak-ming Wong, Consultant Ophthalmologist, Union Hospital, 18 Fu Kin Street, Tai Wai, New Territories, Hong Kong; dralbertcmw{at}gmail.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read the article entitled ‘A randomised placebo-controlled trial of topical steroid in presumed viral conjunctivitis’ by Wilkins and colleagues1 with great interest. Although viral conjunctivitis is typically a self-limiting disease that resolves in 2 weeks, we agree that an agent that reduces clinical symptoms and minimises shedding of infectious virus would be desirable given the morbidity and potential economic impact associated with an outbreak of viral conjunctivitis.2 We have the following observations regarding the methodology and interpretation of the results.

Eighty-eight out of 111 randomised patients returned for review, that is, …

View Full Text

Footnotes

  • Funding The authors received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.